Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide de-escalation in HSCT for genetic lymphohematological diseases
NCT02512679Phase 2Terminated
- Sponsor
- Children's Hospital Los Angeles
- Start
- Feb 2007
- Primary completion
- Sep 2013
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of cyclophosphamide in sickle cell anemia (SCA), thalassemia, Diamond-Blackfan anemia (DBA), combined immunodeficiency (CID), Wiskott-Aldrich syndrome (WAS), sponsored by Children's Hospital Los Angeles. Started Feb 2007; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
sickle cell anemia (SCA)thalassemiaDiamond-Blackfan anemia (DBA)combined immunodeficiency (CID)Wiskott-Aldrich syndrome (WAS)
Beyond the preview
Go deeper on NCT02512679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512679.